OMIX

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC) patients with EGFR or HER2 Mutations

OMIX001475

1Summary
Title A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Chinese Patients with Advanced Non-small Cell Lung Cancer (NSCLC) patients with EGFR or HER2 Mutations
Description This study includes dose escalation and dose expansion parts. Dose expansion was triggered at dose levels that anti-tumor efficacy was observed in EGFR Exon20ins or HER2 Exon20ins patients. The primary objective is to evaluate safety and tolerability and define MTD and RP2D.
Organism Homo sapiens
Data Type Other Type of Genomic Data
Data Accessibility Controlled-access
BioProject PRJCA010938
Release Date 2022-08-03
Submitter mengzhao wang (mengzhaowang@sina.com)
Organization Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Submission Date 2022-08-02
2Files & Download

The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.

File ID File Title Number/Samples File Type File Size File Suffix Download Times Download
OMIX001475-01 Genetics data for WK2 project 1 Other Type of Genomic Data 14.5 KB rar 0 Unavailable

Request for this Data View All Released Data of OMIX